{"id":"vancomycin-plus-rifampin","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"1-5","effect":"Ototoxicity"},{"rate":"5-15","effect":"Red man syndrome (vancomycin)"},{"rate":"1-3","effect":"Hepatotoxicity (rifampin)"},{"rate":null,"effect":"Drug interactions (rifampin)"},{"rate":"2-5","effect":"Thrombophlebitis at infusion site"}]},"_chembl":{"chemblId":"CHEMBL262777","moleculeType":"Small molecule","molecularWeight":"1449.27"},"_fixedAt":"2026-03-30T16:18:22.749682","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, while rifampin inhibits bacterial RNA polymerase to suppress protein synthesis. This combination is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) and other resistant gram-positive bacteria, with demonstrated synergy in treating serious infections including endocarditis and osteomyelitis.","oneSentence":"Vancomycin and rifampin work synergistically to inhibit bacterial cell wall and protein synthesis, providing broad-spectrum bactericidal activity against resistant gram-positive organisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:19.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA)"},{"name":"Bacterial endocarditis"},{"name":"Osteomyelitis and other bone/joint infections"},{"name":"Prosthetic valve infections"}]},"_fixedFields":["pubmed(37)"],"trialDetails":[{"nctId":"NCT06889701","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","startDate":"2025-04-03","conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33},{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT01594827","phase":"PHASE2","title":"Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-10","conditions":"Cystic Fibrosis","enrollment":29},{"nctId":"NCT02443064","phase":"PHASE4","title":"Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2014-01","conditions":"Blood Stream Infections, Endocarditis, MRSA","enrollment":100},{"nctId":"NCT01757236","phase":"PHASE2","title":"Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection","status":"UNKNOWN","sponsor":"University Hospital, Tours","startDate":"2012-10","conditions":"Hip Prosthetic Joint Infection","enrollment":100},{"nctId":"NCT00423982","phase":"PHASE4","title":"Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2006-04","conditions":"Prosthesis-related Infections, Staphylococcal Infections","enrollment":100},{"nctId":"NCT00304811","phase":"PHASE4","title":"Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection","status":"COMPLETED","sponsor":"Michael E. DeBakey VA Medical Center","startDate":"2006-01","conditions":"Staphylococcus Aureus","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"recentPublications":[{"date":"2023 Jul","pmid":"37116243","title":"Staphylococcal biofilm: penetration and bioavailability of vancomycin with or without rifampin.","journal":"Diagnostic microbiology and infectious disease"},{"date":"2018 Mar-Apr","pmid":"29720914","title":"Vancomycin Versus Vancomycin Plus Rifampin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis.","journal":"The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG"},{"date":"2017 Jul","pmid":"28675246","title":"Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant Acinetobacter baumannii causing ventilator-associated pneumonia.","journal":"The new microbiologica"},{"date":"2017","pmid":"28245229","title":"Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infection.","journal":"PloS one"},{"date":"2017 Feb","pmid":"27855069","title":"Activity of Tedizolid in Methicillin-Resistant Staphylococcus epidermidis Experimental Foreign Body-Associated Osteomyelitis.","journal":"Antimicrobial agents and chemotherapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vancomycin plus Rifampin","genericName":"Vancomycin plus Rifampin","companyName":"Michael E. DeBakey VA Medical Center","companyId":"michael-e-debakey-va-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin is a small molecule peptidoglycan inhibitor used to treat various infections, including Staphylococcal Infections and MRSA, often in combination with other treatments such as Rifampin. This combination therapy has been studied in clinical trials for conditions like Prosthesis-related Infections and Endocarditis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}